{"id":5039,"date":"2018-03-01T11:46:45","date_gmt":"2018-03-01T11:46:45","guid":{"rendered":"https:\/\/jurmed.ro\/pacienti\/?p=5039"},"modified":"2018-03-01T11:46:45","modified_gmt":"2018-03-01T11:46:45","slug":"comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor","status":"publish","type":"post","link":"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/","title":{"rendered":"Un nou medicament produs de Roche, pentru tratamentul hemofiliei A cu inhibitor"},"content":{"rendered":"<p style=\"text-align: justify\">Comisia Europeana a aprobat un nou medicament produs de Roche, pentru tratamentul hemofiliei A cu inhibitor<\/p>\n<ul>\n<li style=\"text-align: justify\"><strong>Primul medicament nou aprobat din ultimii 10 ani in Europa pentru pentru tratamentul pacientilor cu hemofilie A care prezinta inhibitor de factor VIII<\/strong><\/li>\n<li style=\"text-align: justify\"><strong>Administrarea subcutanata saptamanala poate reduce povara tratamentului<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify\">Comisia Europeana a aprobat un nou medicament Roche destinat profilaxiei de rutina a episoadelor de sangerare, la persoanele care sufera de hemofilie A care prezinta inhibitor de factor VIII. Acest medicament poate fi utilizat de catre to\u021bi pacien\u021bii, indiferent de varsta. Aproape una din trei persoane care sufera de forme severe ale hemofiliei A poate dezvolta inhibitor la terapia cu inlocuitor de factor VIII, ceea ce cre\u0219te riscul unor sangerari. Aceste sangerari fie pot pune via\u021ba in pericol, fie pot cauza probleme pe termen lung, prin afectarea articula\u021biilor<a href=\"#_ftn1\" name=\"_ftnref1\">[1]<\/a>. Persoanele care sufera de hemofilie A cu inhibitor al factorului VIII prezinta un risc de deces cu 70% mai mare, comparativ cu cei care sufera de forma bolii fara inhibitor<a href=\"#_ftn2\" name=\"_ftnref2\">[2]<\/a>.<\/p>\n<p style=\"text-align: justify\"><em>\u201eAceasta aprobare este o veste foarte buna pentru pacien\u021bii europeni care sufera de hemofilie A cu inhibitor al factorului VIII. \u00a0Apari\u021bia in timp a acestor inhibitori nu doar cre\u0219te riscul unor episoade de sangerari mai dese \u0219i mai grave ci in plus face \u0219i mult mai dificila gestionarea bolii, avand in vedere op\u021biunile terapeutice limitate de pana acum,\u201d<\/em> a afirmat Profesorul Johannes Oldenburg, Institute of Experimental Haematology and Transfusion Medicine, Universitatea din Bonn, Germania. <em>\u201eReducerea sangerarilor \u0219i imbunata\u021birea calita\u021bii vie\u021bii aparute in urma tratamentului cu acest nou medicament, arata poten\u021bialul acestui produs de a imbunatati modul in care este gestionata hemofilia A cu inhibitor.\u201d<\/em><\/p>\n<p style=\"text-align: justify\"><em>\u201eSuntem incantati sa primim aprobarea Comisiei Europene pentru acest medicament, care ofera persoanelor cu hemofilie A cu inhibitor o noua op\u021biune terapeutica, \u00a0prima in ultimii 20 de ani\u201d,<\/em> a afirmat Sandra Horning, Chief Medical Officer \u0219i Head of Global Product Development al grupului Roche. \u201d<em>Noi credem ca acest medicament are poten\u021bialul de a face o diferen\u021ba semnificativa in vie\u021bile persoanelor cu hemofilie A cu inhibitor \u0219i ne exprimam disponibilitatea de a lucra impreuna cu statele membre UE<\/em> <em>in vederea asigurarii accesului cat mai rapid la acest medicament important.\u201d<\/em><\/p>\n<p style=\"text-align: justify\">Comisia Europeana a aprobat acest medicament pe baza a doua dintre cele mai mari studii clinice, in care acest produs a demonstrat eficien\u021ba superioara comparativ cu tratamentele anterioare cu agen\u021bi de bypass, administra\u021bi in profilaxie sau la cerere. Medicamentul a fost deja aprobat in Statele Unite ale Americii de catre U.S. Food and Drug Administration (FDA) la finalul anului trecut.<\/p>\n<p style=\"text-align: justify\">Hemofilia este o boala ereditara grava a sangelui, care face ca sangele unei persoane sa nu se coaguleze corect, ducand la sangerari necontrolabile, care pot avea loc spontan sau in urma unor traumatisme minore.<\/p>\n<p style=\"text-align: justify\">Statisticile arata ca, la nivel global, peste 320.000 de persoane traiesc cu hemofilie de tip A, cea mai des intalnita forma a bolii. Persoanele cu hemofilie A nu au suficient sau deloc factorul de coagulare numit factorul VIII. Lipsa acestui factor impiedica coagularea normala a sangelui. La o persoana sanatoasa, proteinele numite factori de coagulare lucreaza impreuna pentru a forma un cheag de sange \u0219i a opri sangerarea.<\/p>\n<p style=\"text-align: justify\">***<\/p>\n<p style=\"text-align: justify\"><strong>Despre Roche<\/strong><\/p>\n<p style=\"text-align: justify\">Roche este unul din pionerii globali ai industriei farmaceutice \u0219i de diagnostic, ce inoveaza continuu cu scopul de a imbunata\u021bi via\u021ba oamenilor. Sinergia dintre diviziile de Farmaceutice si Diagnostic au transformat Roche in lider global al medicinii personalizate, o strategie care i\u0219i propune sa ofere tratamentul potrivit pentru pacientul potrivit, in cele mai bune condi\u021bii posibile.<\/p>\n<p style=\"text-align: justify\">Roche este cea mai mare companie de biotehnologie la nivel mondial, ce ofera medicamente diferentiate clinic in domeniul oncologiei, imunologiei, bolilor infectioase, oftalmologiei si afectiunilor sistemului nervos central. Roche este, de asemenea, lider mondial in diagnosticul in vitro si in diagnosticul histologic al cancerului, precum si pionier in managementul diabetului. Fondata in 1896, compania Roche este in permanen\u021ba in cautarea celor mai bune solu\u021bii pentru prevenirea, diagnosticarea \u0219i tratarea maladiilor, aducandu-si astfel o contributie sustenabila in societate. Compania doreste de asemenea sa imbunatateasca accesul pacientilor la inovatii medicale prin colaborarea cu toate partile interesate. 30 de medicamente dezvoltate de Roche &#8211; printre care antibiotice, medicamente impotriva malariei si chimioterapice &#8211; sunt pe Lista Medicamentelor Esentiale elaborata de Organizatia Mondiala a Sanatatii. De asemenea, compania Roche a fost recunoscuta opt ani consecutiv ca liderul sectorului farmaceutic al Dow Jones Sustenability Index.<\/p>\n<p style=\"text-align: justify\">Avand sediul central in Basel, Elvetia, Roche este prezenta in peste 100 \u021bari, iar in 2017 compania avea aproximativ 94.000 angaja\u021bi la nivel global. In 2017, Roche a investit 10,4 miliarde de franci elve\u021bieni in cercetare \u0219i dezvoltare, compania raportand vanzari de 53,3 miliarde de franci elve\u021bieni. Compania Genentech, din Statele Unite, este detinuta in totalitate de grupul Roche. De asemenea, Roche este actionarul majoritar al companiei Chugai Pharmaceutical, din Japonia.<\/p>\n<p style=\"text-align: justify\"><strong>Despre Roche Romania<\/strong><\/p>\n<p style=\"text-align: justify\">Prezent pe piata romaneasca inca din perioada interbelica, Roche isi redeschide reprezentanta locala in anul 1992.\u00a0 In anul 2005, grupul Roche ia decizia sa infiin\u021beze societatea comerciala S.C. Roche Romania SRL, urmand ca activitatea reprezentan\u021bei din Bucure\u0219ti sa fie preluata de compania locala nou infiin\u021bata.<\/p>\n<p style=\"text-align: justify\">Roche ofera produse \u0219i servicii care acopera intreg spectrul ingrijirilor de sanatate, pornind de la preven\u021bie, tratament \u0219i pana la monitorizarea post-tratament, in arii terapeutice majore unde exista nevoi medicale neacoperite inca.\u00a0 Prin intermediul Roche Romania, ambele divizii ale Grupului Roche &#8211; divizia de farmaceutice \u0219i divizia de diagnostice &#8211; sunt prezente pe pia\u021ba din \u021bara noastra, oferind produse \u0219i servicii de inalta specializare. Pentru orice informa\u021bii suplimentare, va rugam sa accesa\u021bi <a href=\"http:\/\/www.roche.ro\">www.roche.ro<\/a><\/p>\n<p style=\"text-align: justify\">Departamentul de Comunicare al Roche Romania: <a href=\"mailto:andrei.vlad@roche.com\">andrei.vlad@roche.com<\/a>, 0728292664<\/p>\n<p style=\"text-align: justify\"><a href=\"#_ftnref1\" name=\"_ftn1\">[1]<\/a> European Haemophilia Consortium [Internet; cited 2018 January]. Available from: https:\/\/www.ehc.eu\/bleeding-disorders\/inhibitors\/<\/p>\n<p style=\"text-align: justify\"><a href=\"#_ftnref2\" name=\"_ftn2\">[2]<\/a> www.cdc.gov\/ncbddd\/hemophilia\/features\/inhibitor-severe-hemophilia-a.html<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Comisia Europeana a aprobat un nou medicament produs de Roche, pentru tratamentul hemofiliei A cu inhibitor Primul medicament nou aprobat din ultimii 10 ani in Europa pentru pentru tratamentul pacientilor [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5040,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5039","post","type-post","status-publish","format-standard","has-post-thumbnail","category-stiri-noutati"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Un nou medicament produs de Roche, pentru tratamentul hemofiliei A cu inhibitor - Jurmed - Pacienti<\/title>\n<meta name=\"description\" content=\"hemofilie A cu inhibitor, roche\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/\" \/>\n<meta property=\"og:locale\" content=\"ro_RO\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Un nou medicament produs de Roche, pentru tratamentul hemofiliei A cu inhibitor - Jurmed - Pacienti\" \/>\n<meta property=\"og:description\" content=\"hemofilie A cu inhibitor, roche\" \/>\n<meta property=\"og:url\" content=\"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/\" \/>\n<meta property=\"og:site_name\" content=\"Jurmed - Pacienti\" \/>\n<meta property=\"article:published_time\" content=\"2018-03-01T11:46:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2018\/03\/Roche-Logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"480\" \/>\n\t<meta property=\"og:image:height\" content=\"283\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"costelv\" \/>\n<meta name=\"twitter:label1\" content=\"Scris de\" \/>\n\t<meta name=\"twitter:data1\" content=\"costelv\" \/>\n\t<meta name=\"twitter:label2\" content=\"Timp estimat pentru citire\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/\"},\"author\":{\"name\":\"costelv\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d\"},\"headline\":\"Un nou medicament produs de Roche, pentru tratamentul hemofiliei A cu inhibitor\",\"datePublished\":\"2018-03-01T11:46:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/\"},\"wordCount\":979,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2018\/03\/Roche-Logo.jpg\",\"articleSection\":[\"Stiri \/ Noutati\"],\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/\",\"url\":\"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/\",\"name\":\"Un nou medicament produs de Roche, pentru tratamentul hemofiliei A cu inhibitor - Jurmed - Pacienti\",\"isPartOf\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2018\/03\/Roche-Logo.jpg\",\"datePublished\":\"2018-03-01T11:46:45+00:00\",\"author\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d\"},\"description\":\"hemofilie A cu inhibitor, roche\",\"breadcrumb\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/#breadcrumb\"},\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/#primaryimage\",\"url\":\"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2018\/03\/Roche-Logo.jpg\",\"contentUrl\":\"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2018\/03\/Roche-Logo.jpg\",\"width\":480,\"height\":283},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/jurmed.ro\/pacienti\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Un nou medicament produs de Roche, pentru tratamentul hemofiliei A cu inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/#website\",\"url\":\"https:\/\/jurmed.ro\/pacienti\/\",\"name\":\"Jurmed - Pacienti\",\"description\":\"JURMED \u2013 Jurnal de Sanatate este o publicatie lunara de informare si preventie medicala. Revista si site-ul au un continut bogat de articole si informatii cu adresabilitate catre publicul larg.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/jurmed.ro\/pacienti\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ro-RO\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d\",\"name\":\"costelv\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g\",\"caption\":\"costelv\"},\"url\":\"https:\/\/jurmed.ro\/pacienti\/author\/costelvoicu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Un nou medicament produs de Roche, pentru tratamentul hemofiliei A cu inhibitor - Jurmed - Pacienti","description":"hemofilie A cu inhibitor, roche","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/","og_locale":"ro_RO","og_type":"article","og_title":"Un nou medicament produs de Roche, pentru tratamentul hemofiliei A cu inhibitor - Jurmed - Pacienti","og_description":"hemofilie A cu inhibitor, roche","og_url":"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/","og_site_name":"Jurmed - Pacienti","article_published_time":"2018-03-01T11:46:45+00:00","og_image":[{"width":480,"height":283,"url":"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2018\/03\/Roche-Logo.jpg","type":"image\/jpeg"}],"author":"costelv","twitter_misc":{"Scris de":"costelv","Timp estimat pentru citire":"5 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/#article","isPartOf":{"@id":"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/"},"author":{"name":"costelv","@id":"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d"},"headline":"Un nou medicament produs de Roche, pentru tratamentul hemofiliei A cu inhibitor","datePublished":"2018-03-01T11:46:45+00:00","mainEntityOfPage":{"@id":"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/"},"wordCount":979,"commentCount":0,"image":{"@id":"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/#primaryimage"},"thumbnailUrl":"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2018\/03\/Roche-Logo.jpg","articleSection":["Stiri \/ Noutati"],"inLanguage":"ro-RO","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/","url":"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/","name":"Un nou medicament produs de Roche, pentru tratamentul hemofiliei A cu inhibitor - Jurmed - Pacienti","isPartOf":{"@id":"https:\/\/jurmed.ro\/pacienti\/#website"},"primaryImageOfPage":{"@id":"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/#primaryimage"},"image":{"@id":"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/#primaryimage"},"thumbnailUrl":"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2018\/03\/Roche-Logo.jpg","datePublished":"2018-03-01T11:46:45+00:00","author":{"@id":"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d"},"description":"hemofilie A cu inhibitor, roche","breadcrumb":{"@id":"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/#breadcrumb"},"inLanguage":"ro-RO","potentialAction":[{"@type":"ReadAction","target":["https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/"]}]},{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/#primaryimage","url":"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2018\/03\/Roche-Logo.jpg","contentUrl":"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2018\/03\/Roche-Logo.jpg","width":480,"height":283},{"@type":"BreadcrumbList","@id":"https:\/\/jurmed.ro\/pacienti\/comisia-europeana-aprobat-un-nou-medicament-produs-de-roche-pentru-tratamentul-hemofiliei-cu-inhibitor\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/jurmed.ro\/pacienti\/"},{"@type":"ListItem","position":2,"name":"Un nou medicament produs de Roche, pentru tratamentul hemofiliei A cu inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/jurmed.ro\/pacienti\/#website","url":"https:\/\/jurmed.ro\/pacienti\/","name":"Jurmed - Pacienti","description":"JURMED \u2013 Jurnal de Sanatate este o publicatie lunara de informare si preventie medicala. Revista si site-ul au un continut bogat de articole si informatii cu adresabilitate catre publicul larg.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/jurmed.ro\/pacienti\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ro-RO"},{"@type":"Person","@id":"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d","name":"costelv","image":{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g","caption":"costelv"},"url":"https:\/\/jurmed.ro\/pacienti\/author\/costelvoicu\/"}]}},"_links":{"self":[{"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/posts\/5039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/comments?post=5039"}],"version-history":[{"count":1,"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/posts\/5039\/revisions"}],"predecessor-version":[{"id":5041,"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/posts\/5039\/revisions\/5041"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/media\/5040"}],"wp:attachment":[{"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/media?parent=5039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/categories?post=5039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/tags?post=5039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}